Pregnancy is supposed to come with baby-name debates, midnight cravings, and at least one argument about whether a stroller really needs cup holders. Cancer, on the other hand, arrives with scans, pathology reports, treatment schedules, and a vocabulary nobody wanted to learn. When both happen at once, families often feel as if two worlds have collided in the hallway of a hospital.
That collision is exactly why Dr. Elyce H. Cardonick, a maternal-fetal medicine physician, created the Cancer and Pregnancy Registry. She saw a terrifying gap in medicine: pregnant patients diagnosed with cancer were being asked to make life-changing decisions with too little real-world evidence. Should treatment begin immediately? Could chemotherapy wait? Would the baby be harmed? Would delaying care put the mother at risk? For many families, the available answers were less “evidence-based medicine” and more “educated guessing wearing a white coat.”
The Cancer and Pregnancy Registry was built to change that. By collecting information about pregnant patients with cancer, their treatments, deliveries, outcomes, and children’s long-term development, the registry helps doctors move from fear to facts. It does not make cancer during pregnancy easy. Nothing does. But it makes the conversation more informed, more humane, and far less lonely.
The Medical Problem: Cancer During Pregnancy Is Rare, but Not Rare Enough
Cancer during pregnancy is uncommon, often estimated at about one case per 1,000 pregnancies. That number sounds small until you remember how many pregnancies happen every year. It also becomes more relevant as more people delay childbearing into their 30s and 40s, when certain cancer risks begin to rise.
Rare conditions create a practical problem in medicine: most physicians may see only one or two cases in an entire career. Even excellent oncologists and obstetricians can find themselves facing a situation they have never personally managed before. That is not incompetence; it is math. If each doctor sees only a few cases, no single clinic can easily build enough experience to answer the big questions.
Before registries like this, many pregnant patients were told that cancer treatment and pregnancy were simply incompatible. Some were advised to terminate the pregnancy before starting therapy. Others were encouraged to deliver very early so treatment could begin after birth. In some cases, those recommendations were necessary. In others, they may have been based on fear rather than data.
Who Is Dr. Elyce Cardonick?
Dr. Elyce Cardonick is a board-certified obstetrician-gynecologist and maternal-fetal medicine specialist associated with Cooper University Health Care and Cooper Medical School of Rowan University. Maternal-fetal medicine doctors specialize in high-risk pregnancies, which means they spend their professional lives in the land of “this is complicated, but let’s not panic.”
Her work became focused on cancer and pregnancy after she encountered a pregnant patient with lymphoma in the late 1990s. The patient needed serious treatment, but she also wanted to continue her pregnancy. Dr. Cardonick looked for evidence that could guide care and found that the medical literature could not fully answer the questions patients and doctors were asking. That moment became the seed of the Cancer and Pregnancy Registry.
Instead of accepting that every case had to be treated like a medical cliffhanger, she started collecting cases. Diagnosis by diagnosis, treatment by treatment, child by child, the registry began turning scattered experiences into a growing body of knowledge.
Why a Registry Was the Right Tool
In an ideal research world, doctors would run large clinical trials for every difficult medical question. In the real world, pregnant patients are usually excluded from cancer drug trials because of fetal safety concerns. That creates a frustrating loop: pregnant patients are excluded because safety data are limited, and safety data remain limited because pregnant patients are excluded.
A registry helps break that loop. It does not randomly assign treatment. It does not tell a patient what to do. Instead, it records what actually happened in real clinical care. What type of cancer was diagnosed? At what week of pregnancy? What treatment was used? Was chemotherapy given? Was surgery performed? When did delivery happen? How did the mother do? How did the baby do at birth, and how did the child develop later?
That last question is especially important. A healthy birth is wonderful, but it is not the end of the story. Families also want to know about growth, learning, behavior, heart health, and development years later. The Cancer and Pregnancy Registry is valuable because it follows mothers and children over time, not just through delivery day.
What the Cancer and Pregnancy Registry Collects
The registry gathers confidential information from pregnant patients diagnosed with cancer, often in cooperation with their oncologists, obstetricians, and pediatricians. It may include the cancer type, stage, timing of diagnosis, imaging tests, surgeries, chemotherapy regimens, delivery details, birth outcomes, and follow-up information on the child.
It also includes a separate database for women who become pregnant after a previous cancer diagnosis or treatment. That matters because cancer survivorship has improved dramatically. Many women treated for cancer in childhood, adolescence, or young adulthood later want to start or expand their families. They may worry about fertility, recurrence risk, pregnancy complications, or possible effects of earlier treatment on future children.
By studying both groupswomen diagnosed during pregnancy and women pregnant after cancerthe registry addresses two emotionally loaded questions: “Can I treat cancer while pregnant?” and “Can I safely become pregnant after cancer?” Those are not questions people ask casually over brunch. They are questions that shape families.
What Medicine Has Learned So Far
The most important lesson is not that cancer treatment during pregnancy is always safe. That would be too simple, and medicine rarely does simple unless it is charging for parking. The more accurate lesson is that treatment can sometimes be planned safely, depending on the cancer, the stage, the therapy, and the timing of pregnancy.
For example, many sources now recognize that certain chemotherapy drugs may be used during the second and third trimesters when the benefits justify the risks. The first trimester is usually the most sensitive period because major fetal organs are forming. Surgery may be possible during pregnancy, often with careful coordination. Radiation is more complex and is generally avoided when the fetus could be exposed, though there are rare situations where it may be considered with shielding and expert planning.
Targeted therapies, immunotherapies, hormonal treatments, and newer cancer drugs create harder questions because pregnancy-specific data may be limited or concerning. This is one reason the registry remains essential. Cancer care evolves quickly. Yesterday’s “standard treatment” may become tomorrow’s historical footnote, and pregnancy safety data have to keep up.
Why the Registry Matters for Shared Decision-Making
A pregnant patient with cancer does not need a lecture. She needs a team, a plan, and honest information. The Cancer and Pregnancy Registry supports shared decision-making by helping clinicians explain what is known, what is uncertain, and what has happened in similar cases.
That can change the entire tone of the room. Instead of saying, “We have no idea,” a doctor may be able to say, “There are cases like yours. Here is what was done. Here are the outcomes we know about. Here is what we still cannot promise.” That is not a magic wand, but it is a flashlight in a very dark hallway.
The registry also helps reduce unnecessary fear. Historically, some patients were told that pregnancy termination was the only responsible option after a cancer diagnosis. In some situations, ending a pregnancy may still be part of a medically appropriate discussion. But the registry’s work has helped show that it is not automatically the only path. Some women have received treatment during pregnancy and delivered healthy children.
Real-World Examples Show Why Data Matters
Public reporting on Dr. Cardonick’s work has described patients with lymphoma, ovarian cancer, cervical cancer, and other malignancies who sought guidance after diagnosis during pregnancy. These stories are not fairy tales. They include fear, difficult treatments, premature deliveries, side effects, and uncertainty. But they also show why evidence matters.
One patient might need chemotherapy after the first trimester. Another might need surgery first and medication later. Another might need careful fetal growth monitoring while treatment continues. Another might be advised that immediate treatment is too urgent to delay. The point is not that every patient receives the same answer. The point is that the answer should be individualized, not reflexive.
In cancer during pregnancy, timing is everything. A few weeks can matter for fetal development. A few weeks can also matter for a tumor. The registry helps clinicians understand how similar timing decisions have played out before.
The Emotional Mission: Helping Patients Feel Less Alone
Medical data is powerful, but the registry’s mission is also deeply human. Pregnant patients with cancer often feel isolated because their experience does not fit neatly into either world. In the oncology clinic, they may be the only visibly pregnant patient. In the obstetric clinic, they may be the only patient carrying both a baby and a cancer diagnosis.
Learning that other women have faced the same impossible crossroads can bring relief. It does not remove fear, but it changes the sentence from “I am the only one” to “Someone has walked this road before.” That shift matters.
The registry also gives patients a way to help future families. By contributing their information, they become part of a larger scientific effort. Their experiencegood, bad, complicated, messy, beautifully humancan help another patient years later sit across from a doctor and hear a better answer.
Why Long-Term Follow-Up Is So Important
Birth outcomes are only one chapter. A baby can appear healthy at delivery, but families still want to know how children exposed to cancer treatment in the womb do over time. Do they grow normally? Do they meet developmental milestones? Are there learning or behavioral concerns? Are there heart effects? Are there dental or immune issues? These questions require follow-up beyond the newborn period.
That is why the Cancer and Pregnancy Registry’s long-term approach is so valuable. It follows the health of mothers and children yearly when possible. This kind of follow-up helps doctors separate short-term reassurance from long-term evidence. It also helps identify areas where more careful study is needed.
In medicine, “the baby was born healthy” is wonderful news. But for research, it is not a complete answer. The registry asks what happens next.
How the Registry Improves Care for Doctors Too
The registry is not only for patients. It is also a practical tool for oncologists, obstetricians, maternal-fetal medicine specialists, surgeons, pediatricians, nurses, genetic counselors, and social workers. Cancer during pregnancy requires a team approach because no single specialist owns the whole problem.
An oncologist understands the tumor. A maternal-fetal medicine specialist understands the pregnancy. A surgeon may need to plan an operation. A neonatologist may prepare for a premature birth. A pediatrician may follow the child after delivery. The registry helps all of them speak from a shared evidence base rather than separate islands of expertise.
That cooperation can prevent both overtreatment and undertreatment. A patient should not receive weaker cancer therapy simply because everyone is nervous. She also should not receive a treatment during pregnancy without careful evaluation of fetal risk. Good care lives in the middle: brave enough to treat, cautious enough to plan.
Limitations: What the Registry Cannot Promise
The Cancer and Pregnancy Registry is important, but it is not a crystal ball. It cannot guarantee that a specific treatment will be safe for every patient or every fetus. It cannot replace a personal medical team. It cannot eliminate the emotional weight of choosing between urgent cancer treatment and pregnancy concerns.
Registry data also has scientific limitations. It may include relatively small numbers for rare cancers or newer therapies. Patients who enroll may not represent every patient diagnosed with cancer during pregnancy. Long-term follow-up can be difficult because families move, change doctors, or simply want to close the chapter and live their lives.
Even with these limitations, the registry remains one of the most meaningful ways to gather evidence in a field where randomized trials are often impractical or unethical. In rare, complex medicine, imperfect data can still be far better than silence.
Experience Section: What This Topic Teaches Patients, Families, and Clinicians
One experience repeated again and again in cancer and pregnancy care is the shock of having two timelines suddenly compete. Pregnancy has a calendar: first trimester, anatomy scan, viability, due date. Cancer has its own clock: biopsy, staging, surgery, chemotherapy cycles, response assessment. When those calendars overlap, families quickly learn that medicine is not just science; it is logistics with emotions attached.
A patient may walk into an appointment expecting routine pregnancy news and leave with referrals to oncology. Her partner may be trying to understand medical terms while also wondering how to assemble a crib. Parents and relatives may offer advice, some helpful and some harvested from the internet’s least elegant swamp. In that chaos, a registry-based conversation can be grounding. It gives the family something firmer than panic.
Clinicians also learn humility from these cases. A doctor may be brilliant in breast cancer, lymphoma, or ovarian cancer, yet still need help adapting treatment to pregnancy. A maternal-fetal medicine physician may be expert in fetal monitoring but need oncology input about whether a treatment delay is safe. The best teams are not the ones pretending to know everything. They are the ones willing to gather evidence, call colleagues, review case data, and say, “Let’s build the safest plan we can.”
Another experience is the importance of language. When a patient hears, “You must terminate,” the conversation can feel closed. When she hears, “Here are the risks, here are the options, and here is what similar cases suggest,” the conversation becomes more respectful. The final decision may still be heartbreaking. But the patient is treated as a person with values, not as a problem to be solved quickly.
The registry also teaches that hope and honesty can sit in the same room. Hope does not mean promising a perfect outcome. Honesty does not mean crushing the patient with worst-case scenarios before she has had breakfast. Good counseling explains uncertainty without abandoning the patient inside it. That is especially important in cancer during pregnancy, where families need both medical clarity and emotional oxygen.
For the children whose outcomes are followed, the registry creates a bridge between one family’s crisis and another family’s future. A mother who contributes her information may never meet the patient who benefits from it years later. Still, her experience becomes part of a map. In rare medicine, every carefully documented case is a road sign for the next traveler.
For readers, the lesson is simple but powerful: data is not cold. In the right hands, data is compassion made searchable. The Cancer and Pregnancy Registry exists because one physician recognized that pregnant patients with cancer deserved better than fear, assumptions, and one-size-fits-all advice. They deserved evidence. They deserved follow-up. They deserved to know they were not alone.
Conclusion: A Registry Built From Courage, Science, and Love
Dr. Elyce Cardonick created the Cancer and Pregnancy Registry because medicine needed answers where answers were painfully scarce. Pregnant patients with cancer were facing impossible decisions, and doctors often had too little data to guide them. By collecting real-world information on diagnosis, treatment, pregnancy outcomes, and long-term child development, the registry helps transform isolated cases into useful knowledge.
The work matters because it gives families more than statistics. It gives them context. It helps clinicians counsel with greater confidence. It helps patients understand that cancer during pregnancy does not always mean choosing between treatment and motherhood. Sometimes treatment can be timed. Sometimes pregnancy can continue. Sometimes the safest answer is different from what fear suggests.
No registry can remove the pain of a cancer diagnosis during pregnancy. But the Cancer and Pregnancy Registry does something profoundly important: it replaces medical loneliness with shared knowledge. And in a moment when families are desperate for both hope and truth, that is not a small thing. That is medicine at its most human.
Medical note: This article is for educational purposes only and is not a substitute for professional medical advice. Anyone facing cancer during pregnancy should speak directly with an oncologist, obstetrician, and maternal-fetal medicine specialist.
